Overview

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Status:
Completed
Trial end date:
2019-07-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
Phase:
Phase 2
Details
Lead Sponsor:
Promentis Pharmaceuticals, Inc.
Collaborators:
Baylor College of Medicine
Celerion
Treatments:
Nicotine